Development of a highly selective c-Src kinase inhibitor.
Kristoffer R Brandvold1, Michael E Steffey, Christel C Fox
1Department of Medicinal Chemistry, University of Michigan, 930 N. University Avenue, Ann Arbor, MI 48109, USA.
ACS Chemical Biology
|May 19, 2012
Summary
Researchers developed a novel, highly selective inhibitor for c-Src kinase, a key cancer signaling protein. This targeted approach effectively slowed cancer cell growth, outperforming broader kinase inhibitors and revealing new insights into cancer biology.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Developing selective probes for protein kinase function is crucial for biological studies.
- c-Src is a key signaling kinase implicated in cancer progression.
Purpose of the Study:
- To develop the first highly selective and cell-permeable inhibitor of c-Src.
- To evaluate the efficacy of selective c-Src inhibition in cancer cells.
Main Methods:
- Novel inhibitor design by appending functionality to interact with the phosphate-binding loop of c-Src.
- Testing the inhibitor's selectivity and cell permeability.
- Comparing selective c-Src inhibition with pan-kinase inhibition in cancer cell growth models.
Main Results:
- Successfully developed a highly selective and cell-permeable c-Src inhibitor.
- Selective c-Src inhibition demonstrated superior efficacy in slowing cancer cell growth compared to pan-kinase inhibition.
- Inhibition of c-Abl kinase, an off-target, was found to promote oncogenic cell growth.
Conclusions:
- Selective inhibition of c-Src is a promising strategy for cancer therapy.
- Understanding kinase off-target effects is critical for effective drug development.
- This study provides a valuable tool for interrogating c-Src signaling in cancer.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...